Back to Search Start Over

Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review.

Authors :
Baldassarre LA
Ganatra S
Lopez-Mattei J
Yang EH
Zaha VG
Wong TC
Ayoub C
DeCara JM
Dent S
Deswal A
Ghosh AK
Henry M
Khemka A
Leja M
Rudski L
Villarraga HR
Liu JE
Barac A
Scherrer-Crosbie M
Source :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2022 Oct 18; Vol. 80 (16), pp. 1560-1578.
Publication Year :
2022

Abstract

The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in the field of cardio-oncology and imaging have occurred in recent years. This review presents updated and practical approaches for multimodality cardiovascular imaging in the cardio-oncology patient and provides recommendations for imaging to detect the myriad of adverse cardiovascular effects associated with antineoplastic therapy, such as cardiomyopathy, atherosclerosis, vascular toxicity, myocarditis, valve disease, and cardiac masses. Uniquely, we address the role of cardiovascular imaging in patients with pre-existing cardiomyopathy, pregnant patients, long-term survivors, and populations with limited resources. We also address future avenues of investigation and opportunities for artificial intelligence applications in cardio-oncology imaging. This review provides a uniform practical approach to cardiovascular imaging for patients with cancer.<br />Competing Interests: Funding Support and Author Disclosures Dr Baldassarre has received research funding from the American Heart Association (18CDA34110361) and the National Center for Advancing Translational Science (NCATS), a component of the National Institute of Health (UL1 TR001863). Dr Yang has received research funding from CSL Behring, Boehringer Ingelheim, and Eli Lilly; and has received consultation fees from Pfizer. Dr Zaha is supported by the Cancer Prevention Research Institute of Texas (RP180404). Dr Dent has received research funding and honoraria from Novartis. Dr Deswal is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair. Dr Liu has received research funding from Johnson and Johnson; has received consultation fees from Caption Health and Phillips; and has served on the DMSB for Caelum Biosciences. Dr Scherrer-Crosbie is supported by the National Heart, Lung, and Blood Institute (R01HL130539). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.<br /> (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-3597
Volume :
80
Issue :
16
Database :
MEDLINE
Journal :
Journal of the American College of Cardiology
Publication Type :
Academic Journal
Accession number :
36229093
Full Text :
https://doi.org/10.1016/j.jacc.2022.08.743